Case study: primary biliary cholangitis management with obeticholic acid
This article considers how a patient with primary biliary cholangitis should be managed, following non-response to ursodeoxycholic acid.
A section of liver tissue showing primary biliary cirrhosis, where the bile ducts in the liver are attacked by the body's own immune systemScience Photo Library
After reading this case study you will be able to:
- Identify the symptoms of primary biliary cholangitis and know how the disease is diagnosed;
- Understand the initial treatment options and how treatment response is monitored;
- Understand how suitability for second-line treatment is evaluated.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Last updated
